Hemp/Hashish Franchise Highlights and Recent Essential Gatherings
Given that reporting 3rd quarter earnings, 22nd Century proceeds to place a renewed emphasis on its hemp/cannabis system to target the upstream segments of the cannabinoid price chain, in specific, in the regions of plant biotechnology investigate, gene modification and engineering, modern plant breeding and improvement, and extraction. The Firm believes that it can differentiate by itself in the hemp/cannabis sector by constructing upon its main energy and abilities in plant science and in the component price chain and via its operational partnerships together with the addition of its new operational lover, CannaMetrix. 22nd Century continues to shift its emphasis absent from the currently saturated U.S. client market of cannabidiol (CBD) and hemp-based mostly goods and has refocused its partnership with Panacea, by a non-binding agreement, to provide ingredient cultivation abilities and extraction and purification expert services. The arrangement will provide the Organization with operational assets, together with Needle Rock Farms and many extraction and distillation tools.About the previous yr, the Enterprise has created huge development with KeyGene in its hemp/cannabis investigate. In March 2020, the Business declared that it has developed its proprietary bioinformatics system and can start out monetizing a portion the vast awareness foundation and intellectual house it has produced in excess of the past yr. 22nd Century believes that its collaborative efforts with KeyGene empower the Firm to modify and increase the hemp/hashish plant utilizing the speediest and most price tag-powerful approaches out there. The Firm continues to focus on and produce hemp/cannabis lines with decide on agronomic qualities like strains with secure, extremely-substantial tetrahydrocannabinol (THC) degrees, lines with increased levels of unusual cannabinoids, and traces with ultra-very low terpene stages.On February 10, 2021, 22nd Century Team declared that it has developed and launched a new, reducing-edge technologies platform that will enable the Enterprise and its strategic partners to speedily establish and integrate commercially useful traits of hemp/cannabis crops to produce new, secure hemp/hashish strains. The system, made in collaboration with scientists at KeyGene, incorporates a suite of proprietary molecular tools and a massive library of genomic markers and gene-trait correlations. 22nd Century has now characterised millions of significant-benefit single nucleotide polymorphisms (SNPs). By targeting these newly identified SNPs, the Corporation has been able to identify and isolate unique sections of genetic code from genome assemblies present in the Company’s condition-of-the-art hemp/cannabis bioinformatics databases. This big breakthrough allows 22nd Century Group to quickly and conveniently establish the genes accountable for unique attributes in a plant and is a effective tool for the Company and the hemp/hashish industry. The Corporation has now started discussions to license this system to strategic companions to support them make improvements to their plant breeding methods and improve their hemp/hashish traces.The Company carries on to secure commercially precious patents and intellectual assets through its inside analysis capabilities and external study partnerships. On December 17, 2020, the Corporation introduced that it was granted a new U.S. Patent No. 10,787,674 B2 entitled “Trichome specific promoters for the manipulation of cannabinoids and other compounds in glandular trichomes.” This new mental home permits 22nd Century to build and produce new hemp/cannabis plants that are made to deliver cannabinoids much more effectively by activating the molecular promoters, “on/off switches,” particularly and only in the plant’s trichomes where by the majority of cannabinoids are produced. The patent application describes eight promoters covering all of the significant ways in the cannabinoid biosynthesis pathway and is related to the command of cannabinoid and terpene manufacturing. The Enterprise believes it can monetize a portion of its current hemp/hashish mental home in 2021 and will continue on to carry new, disruptive technologies forward.On March 3, 2021, 22nd Century declared that it has secured an exceptional agreement with CannaMetrix, LLC for the use of their proprietary, human cell-centered testing CannaMetrix EC50Array™ technologies that will enable it to speed up the commercialization of new, disruptive hemp/hashish plant lines and mental property. CannaMetrix’s proprietary CannaMetrix EC50Array™ technology serves as a large-throughput roadmap for acquiring new hemp/cannabis plant traces with tailor-built cannabinoid and terpenoid profiles for use in the existence science, buyer product or service, and pharmaceutical marketplaces. The human cell-based mostly assay has the capacity to measure and validate the efficiency and efficacy of cannabinoids and/or terpenoids by way of outlined biomarkers and receptor action, and can speedily establish ideal plant profiles by measuring the efficiency and outcome on the human mobile technique.22nd Century believes that it can accelerate the growth of commercially, beneficial hemp/hashish traces and relevant mental assets by way of selective partnerships and has now secured four out of the 5 essential partnerships essential to improve each ingredient in the upstream section of the cannabinoid price chain: plant profiling (CannaMetrix), plant biotechnology (KeyGene), plant cultivation (Panacea-Needle Rock Farms), and component extraction/purification (Panacea). The Firm is also in ultimate discussions with best-tier, plant breeders that will be announced soon. The new partnership with CannaMetrix put together with 22nd Century’s around the globe, distinctive arrangement with KeyGene, and the refocused system with its partnership with Panacea will help the Business to provide new commercially valuable hemp/cannabis plant strains to industry in as swiftly as two decades.